MDT Medtronic PLC

Medtronic is the world's largest medical device company, manufacturing products across cardiac rhythm, spinal, neuromodulation, diabetes, and surgical robotics markets. Sector: Healthcare.

Medtronic PLC (MDT) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

From a returns-on-capital standpoint, ROIC is 7.62%, WACC is 7.39%, and the economic spread is 0.24%. On balance, the company clears its capital cost hurdle modestly — value creation is present but not emphatic. Supporting metrics show ROE at 9.44% and ROA at 4.82%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

The company's current market valuation reflects trailing P/E of 24.16, forward P/E of 14.58, PEG of 3.31. The trailing-to-forward compression is present but not extreme — consistent with a company where earnings are expected to grow at a steady rather than exceptional pace. Growth-adjusted valuation is stretched here — the multiple implies either above-consensus growth or a willingness to pay a premium for quality. The aggregate current ratio of 2.54 points to strong liquidity for the company. Across multiples and liquidity, the company is priced in a way that reflects current expectations reasonably well — leaving limited room for error, but also limited near-term downside from valuation compression alone.

On profitability at each income statement layer, gross margin sits at 65.01%, operating margin at 18.66%, and free cash flow margin at 15.25%. Gross margins are well above average, signaling strong production-level economics across the company. At this operating margin level, the the company demonstrate competent cost management and reasonable earnings durability. Free cash flow margins are strong, reflecting capital-efficient businesses that largely self-fund their growth. Taken together, margins are adequate but uneven, suggesting earnings quality is not uniformly strong across all levels.

Looking at growth and market-implied direction, TTM revenue growth of 8.74% indicating top-line growth that is constructive without being speculative. At the same time, the estimated 12-month price change of 27.12%, where implied upside appears constructive but not aggressive. It's worth distinguishing between what businesses are actually delivering and what the market is being asked to believe about the next 12 months. Maintaining alignment between reported results and forward estimates is particularly important in periods where macro uncertainty is elevated. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Putting the pieces together, this is a profile with genuine merit: the numbers support confidence in the forward case without requiring heroic assumptions.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.